In a report released yesterday, George Hill from RBC Capital reiterated a Buy rating on Charles River Labs (CRL), with a price target of $147. The company’s shares closed yesterday at $136.23, close to its 52-week high of $138.89.
According to TipRanks.com, Hill is a 2-star analyst with an average return of 0.0% and a 45.0% success rate. Hill covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Walgreens Boots Alliance, and Cardinal Health.
Currently, the analyst consensus on Charles River Labs is a Hold with an average price target of $133.50, a -2.0% downside from current levels. In a report released yesterday, Robert W. Baird also maintained a Buy rating on the stock with a $148 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $138.89 and a one-year low of $96.70. Currently, Charles River Labs has an average volume of 364.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions.